

What is claimed is:

1. A method for modulating cell proliferation comprising contacting a cell with an agent
5 that modulates the expression of a TRADE α polypeptide or a TRADE β polypeptide such that cell proliferation is modulated.
2. A method for modulating cell proliferation comprising contacting a cell with an agent
that modulates the activity of a TRADE α polypeptide or a TRADE β polypeptide, such that
10 cell proliferation is modulated.
3. The method of claim 1 or 2, wherein the cell is selected from the group consisting of:
an epithelial cell, a ductal epithelial cell, or a bronchial epithelial cell.
- 15 4. The method of claim 1 or 2, wherein the cell is a carcinoma or an adenocarcinoma.
5. The method of claim 1 or 2, wherein the cell is selected from the group consisting of:
a lung cell, a liver cell, a brain cell, and a prostate cell.
- 20 6. The method of claim 2, wherein the agent is a soluble form of a TRADE polypeptide
comprising a TRADE polypeptide extracellular domain.
7. The method of claim 6, wherein the soluble form of the TRADE polypeptide is a
TRADE-Fc fusion protein.
- 25 8. The method of claim 2, wherein the agent consists essentially of a TRADE
polypeptide extracellular domain.
9. The method of claim 1 or 2, wherein the agent is a nucleic acid molecule that
30 modulates expression of a TRADE α polypeptide or a TRADE β polypeptide.

10. The method of claim 9, wherein the agent is a nucleic acid molecule encoding a TRADE α polypeptide or TRADE β polypeptide or portion thereof.

11. The method of claim 9, wherein the agent is a nucleic acid molecule which is antisense to a nucleic acid molecule encoding a TRADE α polypeptide or TRADE β polypeptide or portion thereof.

12. The method of claim 2, wherein the agent is an antibody that recognizes a TRADE family member polypeptide

13. The method of claim 2, wherein the activity is selected from the group consisting of: activation of a JNK signaling pathway, activation of an NF κ B signaling pathway, and activation of apoptosis.

14. A method of modulating the proliferation of a cell comprising contacting a prostate, liver, or lung cell with an agent that modulates the activity of a polypeptide selected from the group consisting of: a TRADE α polypeptide, a TRAIN polypeptide, a α OAF065 polypeptide, and a TRADE β polypeptide.

15. A method of modulating the proliferation of a cell comprising contacting the cell with an agent that modulates the expression of a TRADE family member polypeptide, wherein the cell is selected from the group consisting of an epithelial cell, a ductal epithelial cell, a carcinoma cell, and an adenocarcinoma cell, such that the proliferation of the cell is modulated.

16. A method of modulating the proliferation of a cell comprising contacting the cell with an agent that modulates the activity of a TRADE family member polypeptide, wherein the cell is selected from the group consisting of: an epithelial cell, a ductal epithelial cell, a

carcinoma cell, and an adenocarcinoma cell such that the proliferation of the cell is modulated.

17. The method of claim 15 or 16, wherein the Trade family polypeptide is selected from
5 the group consisting of: TRADE α , TRADE β , Apo4, TRAIN, α OAF065, and β OAF065.

18. The method of claim 15 or 16, wherein the agent is a soluble form of a TRADE family polypeptide comprising a TRADE extracellular domain.

10 19. The method of claim 18, wherein the soluble form of a TRADE family polypeptide is a TRADE-Fc fusion protein.

15 20. The method of claim 15 or 16, wherein the agent consists essentially of a TRADE family extracellular domain.

21. The method of claim 15 or 16, wherein the agent is a nucleic acid molecule that modulates expression of a TRADE family polypeptide.

20 22. The method of claim 15 or 16, wherein the agent is a nucleic acid molecule encoding a TRADE family polypeptide or portion thereof.

23. The method of claim 15 or 16, wherein the agent is a nucleic acid molecule which is antisense to a nucleic acid molecule encoding a TRADE family polypeptide or portion thereof.

25 24. The method of claim 15 or 16, wherein the agent is an antibody that recognizes a TRADE family polypeptide.

25. The method of claim 16, wherein the activity is selected from the group of activities consisting of: activation of a JNK signaling pathway, activation of an NFkB signaling pathway, and activation of apoptosis.

26. A method for modulating the proliferation of a cell comprising contacting the cell with an agent that modulates the expression of a TRADE family member polypeptide, wherein the cell is selected from the group consisting of: a brain cell, a liver cell, a prostate cell, an intestinal cell, or a lung cell, such that the proliferation of the cell is modulated.

27. A method for modulating the proliferation of a cell comprising contacting the cell with an agent that modulates the activity of a TRADE family member polypeptide, wherein the cell is selected from the group consisting of: a brain cell, a liver cell, a prostate cell, an intestinal cell, or a lung cell, such that the proliferation of the cell is modulated.

28. The method of claim 27, wherein the TRADE family member polypeptide is selected from the group consisting of: a TRADE α polypeptide, a TRAIN polypeptide, a α OAF065 polypeptide, and a TRADE β polypeptide.

29. A method for treating a subject having a disorder that would benefit from modulation of expression of a TRADE α polypeptide or TRADE β polypeptide comprising administering to the subject an agent that modulates expression of TRADE α polypeptide or TRADE β polypeptide such that a disorder that treatment occurs.

30. A method for treating a subject having a disorder that would benefit from modulation of activity of a TRADE α polypeptide or TRADE β polypeptide comprising administering to the subject an agent that modulates activity of TRADE α polypeptide or TRADE β polypeptide such that treatment occurs.

31. The method of claim 29 or 30, wherein the disorder is a proliferative disease or disorder selected from the group consisting of: inflammation and neoplasia.

32. The method of claim 31, wherein the neoplasia is a carcinoma.

33. The method of claim 31, wherein the neoplasia is present in lung or prostate tissue.

34. The method of claim 31, wherein the neoplasia is an adenocarcinoma

35. A method for treating a subject having a carcinoma or an adenocarcinoma comprising administering to the subject an agent that modulates activity of a TRADE family polypeptide such that the carcinoma or an adenocarcinoma is treated.

36. A method for treating a subject having a carcinoma or an adenocarcinoma comprising administering to the subject an agent that modulates expression of a TRADE family polypeptide such that a carcinoma or an adenocarcinoma is treated.

37. A method for treating a subject having a carcinoma or an adenocarcinoma of a tissue selected from the group consisting of: lung, liver, brain, and intestine, comprising administering to the subject an agent that modulates activity of a TRADE family polypeptide such that the carcinoma or an adenocarcinoma is treated.

38. A method of detecting a TRADE associated disorder comprising: obtaining a biological sample from a subject and testing for the presence of a TRADE polypeptide in the sample in order to detect a TRADE associated disorder, wherein the sample comprises a cell type selected from the group consisting of: lung cells, liver cells, brain cells, or intestinal cells.